Clinical Trial Update: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating CX-2009 as monotherapy and in combination with CX-072 in advanced breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Neoplasms
• Breast Neoplasms Hormone Receptor Positive
• Breast Neoplasms Triple-negative

Drugs mentioned

• CX-072
• CX-2009

Snippet

Sponsor: CytomX Therapeutics | Conditions: Neoplasms, Breast Neoplasms | Phase 2 | Status: COMPLETED